



BHAGWAN MAHAVEER CANCER HOSPITAL & RESEARCH CENTRE

(Managed by : K.G. Kothari Memorial Trust)

Regd. Office : Jawahar Lal Nehru Marg, JAIPUR-302 017 INDIA

Tel. : 0141-2700107, 2702120, 2702899 Fax : 0141-2702021

E-mail : cancer@datainfosys.net, bmchrc@hotmail.com Web : www.bmchrc.org

No.	Ongoing Clinical Trials	Principal Investigator
1.	Study Title: A Phase III, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus <u>Domvanalimab</u> (AB154) in Participants with Locally <u>Advanced (Stage III), Unresectable Non-Small Cell Lung Cancer</u> Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemoradiation Therapy (<u>PACIFIC-8</u>)	Dr. Aseem K Samar
2.	Protocol Title: An Open Label, Multicenter, <u>Phase IV</u> Study of <u>Teclistamab to Evaluate its Safety in Indian Participants with Relapsed and Refractory Multiple Myeloma</u> who have previously received at least 3 prior lines of therapy including an Immunomodulatory agent, a Proteasome Inhibitor and an Anti-CD38 antibody and have demonstrated disease progression on the last therapy.(Protocol number: 64007957MMY4007)	Dr. Upendra Sahrma
3.	Study Title: A Double-Blind, Randomized, Active Controlled, Parallel Group, Phase 3 Study to Compare Efficacy and Safety of CT-P51 and Keytruda in Combination with Platinum-Pemetrexed Chemotherapy in Patients with Previously Untreated <u>Metastatic Non-Squamous Non-Small Cell Lung Cancer (CT-P51 3.1)</u>	Dr. Deepak Gupta
4.	A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally <u>Advanced Cervical Cancer</u> Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (<u>eVOLVE-Cervical</u>)	Dr. Deepak Gupta
5.	Study Title: A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) in combination with Durvalumab Compared with Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 positive Locally Recurrent Inoperable or <u>Metastatic Triple-negative Breast Cancer (TROPION-Breast05)</u> .	Dr. Deepak Gupta
6.	Protocol Title: A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with <u>Relapsed or Refractory Multiple Myeloma</u> who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide (Protocol number: 64007957MMY3006)- <u>TEC-9</u>	Dr. Upendra Sharma
7.	Ref #: <u>R3918-PNH-2021</u> Protocol: A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria who are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy.	Dr. Upendra Sharma
8.	Protocol Number #: <u>R3918-PNH-2050</u> Protocol: An Open-Label Extension Study to evaluate the Long- Term Safety, Tolerability, and Efficacy of Pozelimab and Cemdisiran Combination therapy In Patients with Paroxysmal Nocturnal Hemoglobinuria.	Dr. Upendra Sharma



BHAGWAN MAHAVEER CANCER HOSPITAL & RESEARCH CENTRE

(Managed by : K.G. Kothari Memorial Trust)

Regd. Office : Jawahar Lal Nehru Marg, JAIPUR-302 017 INDIA

Tel. : 0141-2700107, 2702120, 2702899 Fax : 0141-2702021

E-mail : cancer@datainfosys.net, bmchrc@hotmail.com Web : www.bmchrc.org

9.	Phase 3, Open-Label, Randomized Study of Neoadjuvant Datopotamab Deruxtecan with Durvalumab +/- Chemotherapy followed by Adjuvant Durvalumab, Versus Neoadjuvant Pembrolizumab + Chemotherapy and Adjuvant Pembrolizumab, in Patients with <u>Stage II-III Triple Negative Breast Cancer (TROPION-Breast04)</u>	Dr. Deepak Gupta
10.	Study Title: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With <u>Locally Advanced or Metastatic NSCLC</u> Without Actionable Genomic Alterations (<u>D926NC00001; AVANZAR</u>).	Dr. Deepak Gupta